Keith Katkin Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Keith Katkin.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Keith Katkin. Keith Katkin is Sr. V.P. of Sales & Marketing in AVANIR PHARMACEUTICALS, INC. ($AVNR) and Director in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in Carbylan Therapeutics, Inc. ($CBYL) and in Syndax Pharmaceuticals Inc ($SNDX) and Director in Novus Therapeutics, Inc. ($NVUS) and PEO;CEO-Urovant Sciences,Inc. in Urovant Sciences Ltd. ($UROV) and PEO;CEO/Urovant Sciences, Inc. in Urovant Sciences Ltd. ($UROV).
Latest Insider Trading Transactions of Keith Katkin
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVNR, ELDN, KALV, RIGL, SNDX, UROV
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Sep 15 2020 | NVUS | Novus Therapeutics ... | Katkin Keith | Director | Option Exercise | A | 500.00 | 5,907 | 2,953,500 | 5,907 | |
| May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
| May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
| Feb 21 2020 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Option Exercise | M | 3.86 | 180,000 | 694,800 | 701,254 | |
| Feb 21 2020 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Sell | J | 13.08 | 75,212 | 983,773 | 199,680 | 274.9 K to 199.7 K (-27.36 %) |
| Feb 21 2020 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Payment of Exercise | F | 13.08 | 104,788 | 1,370,627 | 274,892 | 379.7 K to 274.9 K (-27.60 %) |
| Feb 21 2020 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Buy | M | 3.86 | 180,000 | 694,800 | 379,680 | 199.7 K to 379.7 K (+90.14 %) |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 9.47 | 24,000 | 227,280 | 24,000 | ||
| Jan 09 2020 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Grant | A | 0.00 | 199,680 | 0 | 199,680 | 0 to 199.7 K |
| Dec 11 2019 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Option Exercise | M | 3.86 | 120,000 | 463,200 | 881,254 | |
| Dec 11 2019 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Sell | S | 12.78 | 120,000 | 1,533,600 | 0 | 120 K to 0 (-100.00 %) |
| Dec 11 2019 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Buy | M | 3.86 | 120,000 | 463,200 | 120,000 | 0 to 120 K |
| Jul 15 2019 | NVUS | Novus Therapeutics ... | Katkin Keith | Director | Option Exercise | A | 0.88 | 20,000 | 17,600 | 20,000 | |
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
| Jan 08 2019 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO/Urovant Sci ... | Option Exercise | A | 6.88 | 350,250 | 2,409,720 | 350,250 | |
| Oct 17 2018 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO-Urovant Sci ... | Option Exercise | A | 13.65 | 99,967 | 1,364,550 | 99,967 | |
| Oct 03 2018 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO-Urovant Sci ... | Option Exercise | A | 3.86 | 200,250 | 772,965 | 200,250 | |
| Sep 28 2018 | UROV | Urovant Sciences L ... | Katkin Keith | PEO;CEO-Urovant Sci ... | Option Exercise | A | 14.00 | 39,815 | 557,410 | 39,815 | |
| Jun 14 2018 | NVUS | Novus Therapeutics ... | Katkin Keith | Director | Option Exercise | A | 6.18 | 9,100 | 56,238 | 9,100 | |
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
| Mar 31 2017 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 13.78 | 25,000 | 344,500 | 25,000 | ||
| May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
| Aug 05 2015 | CBYL | Carbylan Therapeut ... | Katkin Keith | Director | Option Exercise | A | 6.91 | 29,000 | 200,390 | 29,000 | |
| Jul 01 2015 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 3.26 | 80,000 | 260,800 | 80,000 | |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Grant | A | 0.00 | 57,600 | 0 | 60,100 | 2.5 K to 60.1 K (+2,304.00 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Buy | P | 9.00 | 1,700 | 15,300 | 2,500 | 800 to 2.5 K (+212.50 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Buy | P | 8.98 | 800 | 7,184 | 800 | 0 to 800 |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Option Exercise | A | 2.92 | 30,000 | 87,600 | 30,000 |
Page: 1